Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 130
Microbial Status and Genetic Evaluation of Mice and Rats: PROCEEDINGS OF THE 1999 US/JAPAN CONFERENCE Defining Phenotype in Genetically Engineered Mice Norikazu Tamaoki Tokai University School of Medicine Kanagawa, Japan INTRODUCTION Genetically engineered mice have become popular tools in recent biomedical research. However, only a few among thousands of genetically engineered mice so far reported have been established as laboratory animals that have controlled quality and are being produced and used on a large scale. The aims of defining phenotype in genetically engineered mice are as follows: (1) to define clearly the difference between genetically engineered animals produced for the purpose of elucidating the function of a gene or genes in vivo and laboratory animals used as a tool for studying the mechanism of diseases or testing drugs in vivo; and (2) to define clearly the difference among “genotype, ” “phenotype,” and “dramatype.” Dramatype, which is an altered function of the organism induced by changes in the environment and phenomena seen in the disease state, is the most important characteristic of laboratory animals. HISTORICAL DEVELOPMENT The following two examples of genetically engineered mice have been developed as useful laboratory animals in the biomedical field: the TgPVR21 mouse (poliovirus receptor transgenic mouse) and the ras H2 mouse (human proto-ras transgenic mouse).
OCR for page 131
Microbial Status and Genetic Evaluation of Mice and Rats: PROCEEDINGS OF THE 1999 US/JAPAN CONFERENCE TgPVR21 Mouse (Poliovirus Receptor Transgenic Mouse) 1990-1991: Establishment of human poliovirus receptor transgenic mice 1991-1993: Establishment as a laboratory animal (standardization of characters and successful large-scale production) and development of methods for neurovirulence testing and safety assurance by castration (Levenbook and Nomura 1997) 1993-1995: World Health Organization (WHO) collaborative study of TgPVR21, 1st phase 1995-1997: WHO collaborative study of TgPVR21, 2nd phase 1997-1999: WHO collaborative study of TgPVR21, 3rd phase 1999: Approval of neurovirulence test of oral poliovirus vaccine alternative for monkeys by WHO Expert Committee on Biological Standardization ras H2 Mouse (Human Proto-ras Transgenic Mouse) 1988: Establishment of human proto-ras gene transgenic mouse 1990-1992: Backcrossing and establishment of congenics 1992-1996: Validation study for carcinogenicity testing in Japan (Yamamoto and others 1998) 1996-1999: Validation study for rapid carcinogenicity testing in the United States, the European Union, and Japan CONCLUSIONS As shown above, establishment of a novel laboratory animal from a genetically engineered animal is a lengthy process and requires many steps as follows: (1) establishing of a genetically engineered animal; (2) phenotyping and selection of candidate animals; (3) study of functions in purpose-oriented environments or experimentation (dramatyping); and (4) establishment of a human disease model as a laboratory animal. REFERENCES Levenbook, I., and T. Nomura. 1997. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice. Lab. Anim. Sci. 47:118-120. Yamamoto, S., K. Urano, H. Koizumi, S. Wakana, K. Hioki, K. Mitsumori, Y. Kurokawa, Y. Hayashi, and T. Nomura. 1998. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ. Health Perspect. 106(Suppl 1):57-69.
Representative terms from entire chapter: